Radiopharmaceuticals Market Growth

Radiopharmaceuticals Market Growth is Anticipated at CAGR of 10.6%; Market Value to Grow to USD 54.6 Billion by 2040 | Roots Analysis

According to a recently published report by Roots Analysis, the rising prevalence of chronic diseases, technological advancements and development of advanced radioligand therapies is driving the growth of radiopharmaceuticals market

Global Radiopharmaceuticals Industry Overview

The global radiopharmaceuticals market is expected to reach around USD 54.6 billion by 2040, growing at a CAGR of 10.6% during the forecast period till 2040.

Given the rising geriatric population, along with the increasing prevalence of chronic diseases and surge in imaging procedures using radionuclides, the demand for innovative radiopharmaceuticals has grown significantly. Moreover, several challenges associated with the conventional diagnostic and therapeutic techniques, such as procedural complexities, lengthy processing time and lower clinical success rates have prompted a shift towards more advanced modalities in modern medicine like radiopharmaceuticals.

In fact, due to their high target specificity and therapeutic efficacy, radiopharmaceuticals have revolutionized the diagnosis and treatment of several chronic diseases (particularly cancer). Notably, over 50 million nuclear medicine procedures are performed globally each year, offering critical insights into organ function and the diseases progression.

Further, the ongoing technological advancements (such as development of novel isotopes, advent of alpha therapies, and improved imaging modalities like PET), coupled with AI-powered algorithms, radiopharmaceuticals present a transformative opportunity to enhance efficiency and accuracy across various healthcare applications.

Browse ~135 figures and ~120 market data tables spread across 275 slides and detailed Table of Content on “Global Radiopharmaceuticals Market, till 2040 by Purpose of Radiopharmaceutical (Diagnostics and Therapeutics), Type of Diagnostic Radiopharmaceutical (PET and SPECT), Type of Emitter (beta, gamma and other emitters), Technetium-99m, Fluorine-18, Iodine-131, Leutetium-177, Gallium-68 and Other Radioisotopes), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Hormonal Disorders, Gastrointestinal Disorders and Other Disorders), End Users (Hospitals, Diagnostic Centers and Research Institutes), Geographical Regions and Key Players” here: https://www.rootsanalysis.com/reports/radiopharmaceuticals-market.html

Market Drivers

Several factors are propelling the growth of the global radiopharmaceuticals market. One of the key factors driving the future of this market is the growing prevalence of cancer. According to the World Health Organization, by 2050, new cancer cases are expected to exceed 35 million, representing approximately 80% increase from the number of cases reported in 2022. This has intensified the demand for radiopharmaceuticals to enable highly targeted cancer diagnosis and treatment.

In addition, the integration of cutting-edge imaging technologies, such as PET and SPECT scanners, coupled with the growing preference for precision medicine approaches, has played a pivotal role in expanding the applications of radiopharmaceuticals. Further, considering the increasing pace of innovation, funding and research activity in this domain, the radiopharmaceuticals market is anticipated to witness a steady growth in the foreseen future.

Market Restraints

While the global radiopharmaceuticals market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary challenges is navigating the complex regulatory landscape involved in the approval and licensing of radiopharmaceutical production and handling facilities. Further, stringent safety and compliance requirements mandated by regulatory bodies, such as the Nuclear Regulatory Commission (NRC) and Atomic Energy Regulatory Board (AERB), pose significant hurdles.

Additionally, the short half-life of various radioisotopes used in radiopharmaceuticals creates logistical constraints, necessitating rapid production and distribution to ensure clinical efficacy. Moreover, limited availability of key radioisotopes, high production costs, and a fragile, time-sensitive supply chain further complicate large-scale adoption, making the consistent delivery of radiopharmaceuticals a persistent industry challenge.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global radiopharmaceuticals market forward. One notable factor is the increased funding initiatives for nuclear medicine research. This increased investment is further fueling innovation and accelerating the development of advanced radiopharmaceuticals, which hold great potential for improving the diagnostic accuracy and effectiveness of the therapies.

Further, governments are actively supporting large-scale production and innovation in radiopharmaceuticals. For instance, in 2024, the Dutch government allocated funds worth EUR 10.5 million to enhance the production of radioisotopes, such as Terbium-161 for the treatment of cancer. In addition, the expanding applications of radiopharmaceuticals in personalized medicine is enabling the development of targeted radionuclide therapies tailored to individual patient profiles, thereby improving therapeutic outcomes.

The industry is also witnessing rapid expansion in emerging markets and growing momentum in global partnerships and acquisitions, ultimately broadening access to advanced treatments. As a result, the global radiopharmaceutical market is well-positioned for substantial growth in the foreseen future.

Global Radiopharmaceuticals Market Segments

Based on the purpose of radiopharmaceutical, the market is segmented into diagnostics and therapeutics.

• The diagnostics segment led the global radiopharmaceutical market, capturing the largest revenue share of more than 50% in the current year.
• The therapeutic segment is anticipated to grow at a higher CAGR of 13.3%, during the forecast period.

Based on the type of diagnostic radiopharmaceutical, the market is segmented into PET radiopharmaceuticals and SPECT radiopharmaceuticals.

• The SPECT radiopharmaceutical segment led the global radiopharmaceutical market, capturing the largest revenue share of close to 70% in the current year.
• The PET radiopharmaceutical segment is anticipated to grow at a higher CAGR of 11.8%, during the forecast period.

Based on the type of emitter, the market is segmented into gamma emitters, beta emitters and other emitters.

• The gamma emitters segment led the global radiopharmaceutical market, capturing the largest revenue share of over 75% in the current year.
• The beta emitters segment is anticipated to grow at a higher CAGR of 12.6% during the forecast period.

Based on the type of radioisotope, the market is segmented into Technetium-99m, Fluorine-18, Iodine-131, Leutetium-177, Gallium-68 and other radioisotopes.

• The Technetium-99m radioisotope segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 80% in the current year.
• The Leutetium-177 radioisotope segment is anticipated to grow at a higher CAGR of 15.0% during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, neurological disorders, hormonal disorders, gastrointestinal disorders and other disorders.

• The oncological disorders segment led the global radiopharmaceuticals market, capturing the largest revenue share of around 40% in the current year.
• The neurological disorders segment is anticipated to grow at a higher CAGR of 11.5% during the forecast period.

Based on the end users, the market is segmented into hospitals, diagnostic centers and research institutes.

• The hospitals segment led the global radiopharmaceuticals market, capturing the largest revenue share of close to 50% in the current year.
• The research institutes segment is anticipated to grow at a higher CAGR of 11.4% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

• North America dominated the global radiopharmaceuticals market and accounted for the largest revenue share of around 45% in the current year.
• The global radiopharmaceuticals market growth in Asia-Pacific region is anticipated at a higher CAGR of 12.0%, during the forecast period.

Key Companies Profiled

The global radiopharmaceuticals market report also includes detailed profiles of key players (listed below) that are engaged in developing radiopharmaceuticals:

• Bayer
• Bracco
• Eli Lilly
• GE HealthCare
• ITM Isotope Technologies
• Jubilant Radiopharma
• Lantheus
• Novartis
• Telix Pharmaceuticals

You Can Download Free Sample PDF Copy of This Report At: https://www.rootsanalysis.com/reports/radiopharmaceuticals-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com